Companies / Rein Therapeutics, Inc.

Rein Therapeutics, Inc.

Nasdaq: RNTXCIK 1420565AUSTIN, TX
Insider flow · last 90 daysNet buys $49.6K

Financials · FY2025

Revenue$0
Net income$-49.87M
Total debt—
Cash$4.45M
Diluted EPS$-1.96
Shares outstanding85.5M

Ownership

85.5M shares outstanding · as of May 13, 2026
0.07%Insiders
Ownership
Insiders0.07%62,514
10%+ / strategic5.26%4,500,000
Institutions13.54%11,580,884
Public float81.13%69,395,634

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 1

View all →
Insider% of sharesShares
Von Rickenbach Josef HDirector
0.07%62,514

Institutional holders 47

View all →
HolderValue% of shares
Voss Value Master Fund, LP$4.92M4.96%
BIOS Capital Management, LP$1.96M1.98%
Vanguard Group Inc$1.35M1.36%
University of TEXAS/TEXAS Am Investment Management Co$665.1K0.60%
Prosight Management, LP$513.4K0.52%
Cable Car Capital, LP$487.2K0.49%
Geode Capital Management, LLC$448.2K0.40%
State Street Corporation$394.8K0.44%
Sigma Planning Corp$367.8K0.41%
BlackRock, Inc.$339.3K0.38%

Activity

View all →
InsidersInstitutions
What insiders are doing in this stock (Form 4).
DateActorActionSecurityValueShares ΔPosition afterImpact
May 26, 2026Von Rickenbach Josef H
Director
BuyCommon stock , $0.001 par value$24.5K+23K
+66.59%
58,014
0.07% of shares
low
May 22, 2026Von Rickenbach Josef H
Director
BuyCommon stock , $0.001 par value$16.7K+16K
+84.51%
34,824
0.04% of shares
low
May 27, 2026Von Rickenbach Josef H
Director
BuyCommon stock , $0.001 par value$4.8K+5K
+7.76%
62,514
0.07% of shares
low
May 21, 2026Von Rickenbach Josef H
Director
BuyCommon stock , $0.001 par value$3.6K+3K
+22.13%
18,874
0.02% of shares
low

5%+ ownership events

Schedule 13D / 13G
FilerStance% of classSharesDate
Voss Value Master Fund, LPPassive13G/A———
Lytton Laurence WPassive13G—4,500,000—

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
RNTX——00887A204—